Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2599506 in Type 2 Diabetes
NCT01024244Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of LY2599506 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin A1c at 12 weeks. Started Dec 2009; status: terminated.
02
Drugs
LY2599506
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01024244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024244.